Sign In
Buy COLL
$34.82
-0.410 (-1.16%)
At Close: Jul 13, 2026
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
10:41am, Thursday, 09'th Jul 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
09:26am, Wednesday, 08'th Jul 2026
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
New Strong Buy Stocks for July 6th
05:36am, Monday, 06'th Jul 2026
BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
11:45am, Wednesday, 01'st Jul 2026
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
10:40am, Tuesday, 23'rd Jun 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Jun 2026
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
08:00am, Wednesday, 27'th May 2026
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global H
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
07:31am, Tuesday, 12'th May 2026
- Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio - - Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expecte
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
07:31am, Tuesday, 12'th May 2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
01:51pm, Thursday, 07'th May 2026
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 07'th May 2026
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wal
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
09:56am, Thursday, 07'th May 2026
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.42 per share. This compares to earnings of $1.49 per share a year ago.
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
07:30am, Thursday, 07'th May 2026
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close A
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
11:06am, Thursday, 30'th Apr 2026
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
08:00am, Thursday, 23'rd Apr 2026
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on�
